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AbsTRACT
Gadolinium-based contrast media are widely used in 
cardiovascular MRI to identify and to highlight the 
intravascular and extracellular space. After gadolinium, 
manganese has the second highest paramagnetic 
moment and was one of the first MRI contrast 
agents assessed in humans. Over the last 50 years, 
manganese-enhanced MRI (MEMRI) has emerged 
as a complementary approach enabling intracellular 
myocardial contrast imaging that can identify functional 
myocardium through its ability to act as a calcium 
analogue. Early progress was limited by its potential 
to cause myocardial depression. To overcome this 
problem, two clinical formulations of manganese were 
developed using either chelation (manganese dipyridoxyl 
diphosphate) or coadministration with a calcium 
compound (EVP1001-1, Eagle Vision Pharmaceuticals). 
Preclinical studies have demonstrated the efficacy 
of MEMRI in quantifying myocardial infarction and 
detecting myocardial viability as well as tracking altered 
contractility and calcium handling in cardiomyopathy. 
Recent clinical data suggest that MEMRI has exciting 
potential in the quantification of myocardial viability 
in ischaemic cardiomyopathy, the early detection of 
abnormalities in myocardial calcium handling, and 
ultimately, in the development of novel therapies 
for myocardial infarction or heart failure by actively 
quantifying viable myocardium. The stage is now set 
for wider clinical translational study of this novel and 
promising non-invasive imaging modality.
InTRoduCTIon
Cardiovascular MRI is an essential tool in the diag-
nosis of a range of cardiovascular diseases. Signif-
icant advances in expertise, technical capabilities 
and accessibility mean cardiac MRI is a routine 
clinical assessment. It is the accepted gold-standard 
method for quantification of myocardial volumes, 
mass and function, with an increasing role in 
valvular heart disease. Contrast imaging with gado-
linium delayed-enhancement MRI (DEMRI) allows 
quantification of myocardial fibrosis, especially 
for assessment of myocardial viability in ischaemic 
cardiomyopathy. However, DEMRI only allows 
extracellular space imaging, describing infarcted or 
scarred tissue, from which myocardial viability is 
inferred. By comparison, manganese-enhanced MRI 
(MEMRI) directly provides intracellular contrast of 
viable myocardium. Furthermore, long-term safety 
questions have been raised regarding some gado-
linium formulations.1 This review explores the 
potential of novel manganese-based contrast agents 
in MRI, providing a synopsis of published work 
since the comprehensive review by Wendland 15 
years ago,2 and discussing future potential clinical 
applications of MEMRI of the myocardium.
HIsToRICAl peRspeCTIve: MAngAnese As A 
ConTRAsT AgenT
Paramagnetic compounds have long been used 
in MRI to modify relaxivity, providing contrast 
enhancement for tissue characterisation. Gadolin-
ium-based chelates dominate current clinical use. 
Their size and physical properties prevent them 
crossing intact cell membranes and they initially 
disperse equally throughout extracellular space. 
Tissues with abnormal extracellular dynamics clear 
gadolinium more slowly, resulting in reduced T1 in 
pathological regions.
Manganese was the first element used as an MRI 
contrast agent in vivo, with significant cardiac, 
hepatic and renal uptake causing marked short-
ening of T1 relaxation.3 Manganese is an essential 
trace element required as a cofactor and enzyme 
activator for bone development, neurological, 
immunological and endocrine function, and is also 
key to protecting mitochondrial membranes from 
oxidative stress through superoxide dismutase.4 
The impact of manganese-protein binding on 
proton relaxation was first studied in 1962 and in 
1973, Lauterbur used manganese to image differ-
ential T1 relaxation using nuclear magnetic reso-
nance.5 Manganese has key properties of interest 
for MRI. First, its paramagnetism reduces T1 relax-
ation of water, enabling contrast in tissues where it 
accumulates, providing excellent anatomical delin-
eation.6 Second, it is a calcium analogue, crossing 
myocardial L-type voltage-gated calcium channels 
and sodium-calcium exchangers.7 Third, its natural 
occurrence in vivo as an essential trace element 
makes its safety and toxicity profile more attractive 
than gadolinium which has no known mammalian 
biological role.8
Manganese contrast agents offer potential in 
numerous MRI platforms having been applied to 
preclinical neuronal assessment,6 lymphocyte and 
stem cell tracking,9 pancreatic beta cell activa-
tion10 and the evaluation of myocardial viability 
in ischaemia.11 Manganese radiotracers have also 
been explored in positron emission tomography.12 
Interest in the field is evidenced by a steady increase 
in publications over the past 15 years.
CAlCIuM-dependenT MyoCARdIAl ConTRAsT 
IMAgIng
Unlike gadolinium, manganese provides intra-
cellular myocardial contrast imaging through 
calcium handling. During myocardial contraction, 
calcium enters cardiomyocytes predominantly 
through voltage-gated L-type calcium channels trig-
gering calcium release from the sarcoendoplasmic 
reticulum (excitation–contraction coupling).13 
In diastole, calcium is actively transported into 
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sarcoendoplasmic reticulum by calcium ATP (SERCA2a), in 
addition to passage into the extracellular space via the sodium–
calcium exchanger and mitochondrial uptake.13 Alterations in 
calcium handling by protein dysfunction and defective regula-
tory mechanisms impair the myocyte’s ability to increase and to 
decrease intracellular calcium concentrations, impacting systole 
and diastole accordingly.14 Its fundamental role in excitation–
contraction coupling makes calcium handling central to patho-
physiological and adaptive mechanisms of defective contractile 
function and impaired relaxation in cardiomyopathy. Several 
studies have demonstrated reduced sarcoendoplasmic retic-
ulum calcium storage and release, with decreased SERCA2a 
and upregulated sodium–calcium exchanger activity.15 Altered 
expression and activity of voltage-gated L-type calcium channels 
in heart failure and hypertrophy observed in several studies are 
incompletely understood,16 although highlight the centrality of 
calcium handling to cardiomyocyte dysfunction.
The major interest in manganese lies in its biological func-
tionality. As a calcium analogue, manganese is taken up avidly 
by voltage-gated calcium channels into cells with active 
calcium handling. Correspondingly, its uptake is reduced or 
absent in stunned or infarcted tissue, respectively.17 The resulting 
reduction of T1 relaxation times in tissue with functioning 
calcium handling hypothetically enables selective identifica-
tion of viable cardiomyocytes. While DEMRI with gadolinium 
demarcates tissues with pathological extracellular space and 
scar, MEMRI has the ability to label viable myocardium directly, 
marking non-viability with reduced manganese uptake by 
reduced or absent T1 shortening.
oveRCoMIng ToxIC poTenTIAl of MAngAnese
Most human exposure to manganese occurs naturally as it 
is present in nearly all diets, with stable levels maintained by 
homoeostatic mechanisms almost regardless of intake.18 Natu-
rally occurring deficiency is rare, but toxicity from overexposure 
are recognised, often following environmental or occupational 
contact.19 With toxic exposure, manganese can accumulate in 
the striatum and globus pallidus, manifesting as headache and 
emotional lability, with parkinsonian extrapyramidal symptoms 
and gait-disturbance (collectively termed manganism).20 In its 
early development, cardiovascular toxicity occurred in animal 
studies with administration of manganese chloride because it 
competed too strongly with myocardial calcium uptake, causing 
myocardial depression, hypotension and cardiac arrest.21 
MEMRI remained underdeveloped for many years due to initial 
safety concerns and concomitant advances in gadolinium-based 
imaging techniques.
Substantial subsequent work has sought to overcome poten-
tial manganese toxicity. For intracellular myocardial imaging, 
manganese must be freely circulating for cardiomyocyte uptake. 
Unlike agents which strongly bind manganese without dissoci-
ating, formulations have been developed which negate risks of 
toxicity while simultaneously maintaining the desired magnetic 
and kinetic properties for myocardial imaging. To date, two 
different methods have been employed producing distinct 
clinical-grade agents, both with excellent safety profiles: (1) 
chelation, producing lower effective circulating molar dose of 
manganese, and (2) coadministration with calcium, competing 
with manganese at the sarcolemmal membrane to reduce cardio-
toxicity. The two most clinically relevant formulations are 
discussed in table 1.
Manganese dipyridoxyl diphosphate
Unlike gadolinium chelates designed not to dissociate, dipyri-
doxyl diphosphate chelation allows manganese to uncouple 
and circulate as a protein-bound complex, with the majority of 
manganese cleared through hepatobiliary excretion (<20% renal 
excretion).22 Following administration, biotransformation of 
manganese dipyridoxyl diphosphate (MnDPDP) occurs by 
dephosphorylation and transmetallation with zinc, facilitating 
MRI-detectable intracellular manganese uptake as demonstrated 
in vitro where tissue uptake and renal clearance occur rapidly.23 
These findings have been reinforced in subsequent animal24 and 
human studies.25 Administering manganese in this way success-
fully mitigates toxicity while retaining crucial paramagnetic and 
biological properties for adequate intracellular MRI contrast. 
In phases I and II trials, MnDPDP was well tolerated, with 
minor and transient symptoms of flushing, headache and nausea 
reported in a minority of recipients with more serious adverse 
events occurring rarely.26 MnDPDP is an established clinical 
agent with utility in the diagnosis and staging of hepatobiliary 
neoplasms,27 which was superceded by gadolinium-based agents 
Table 1 Status of manganese contrast agents with clinical experience in myocardial imaging
Contrast agent




barriers to clinical 
application
Currently recruiting or yet-




5 Previously licensed in EU
Phase III clinical trials 
complete
Previously available as 
Teslascan*, withdrawn due 
to lack of demand
No current clinical 
production
Manganese-enhanced MRI 
(MEMRI) of the myocardium
(NCT03607669)
Non-chelated manganese:
  MnCl2† 5 Not licensed or undergoing 
clinical trial
Not available Significant cardiotoxic 
potential in cardiac patients
None
  EVP1001-1 1–10 Phase II clinical trials 
complete
Not available Currently undergoing 
further clinical trial
Toxicity profile in 
cardiac patients not well 
established
Clinical Trial of MEMRI to 
assess peri-infarct Injury
(NCT02933034)
Efficacy of EVP1001-1 
(see more) in the Assessment 
of myocardial viability in 
patients With cardiovascular 
disease
(NCT01989195)
*Marketing authorisation holder: GE Healthcare AS.
†No current plans for routine clinical use at time of writing due to toxicity profile.
EU, European Union; EVP1001-1, Eagle Vision Pharmaceutical; MnCl2, manganese chloride; MnDPDP, manganese dipyridoxyl diphosphate. 
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for upper gastrointestinal indications, market authorisation 
being withdrawn for economic reasons.
evp1001-1
Eagle Vision Pharmaceuticals, (Downingtown, USA) has devel-
oped patented an alternative method to chelation of countering 
adverse effects from manganese, reconstituting magnesium 
gluconate with a source of calcium.28 In this form, manganese 
has a short plasma half-life, rapid myocardial uptake and slow 
clearance, with little redistribution.29 At the time of writing, the 
precise details of the formulation are not publicly available with 
clinical trials ongoing. Limited available data from one clinical 
study (NCT01989195) did not report any adverse side effects, 
where oral antiemetic was given prior to administration of the 
agent.
pReClInICAl sTudIes wITH  MeMRI
The myocardial uptake and dynamics of manganese are reviewed 
in detail elsewhere.2 In brief, evaluation of dose–response curves 
initially suggested a linear relationship between manganese chlo-
ride and myocardial signal intensity,30 but subsequent studies 
have shown that the relationship between manganese dose and 
change in relaxivity is more accurately described by two linear 
uptake patterns with a plateau phase at very high doses, likely 
attributable to rate-limiting renal and biliary excretion.31 Impor-
tantly, the dose–response relationship appears linear up to a dose 
of approximately 165 μmol/kg, over 30 times the clinical dose 
proposed for cardiac imaging. While calcium influx is predom-
inantly dependent on voltage-gated calcium channels, efflux 
from the myocardium appears more related to sodium–calcium 
exchangers. Thus, the rate of efflux increases exponentially with 
increasing manganese dose and is reduced by a sodium–calcium 
exchange inhibitor.32 These comprehensive preclinical dose–
response studies support the feasibility of quantitative analysis 
of the effect of manganese in the heart.
Myocardial infarction and MeMRI
Various studies have investigated quantification of myocardial 
infarction with MEMRI. While most use coronary artery liga-
tion or occlusion models, one study demonstrated that MEMRI 
could differentiate normal from infarcted myocardium in a 
model of chronic cryoinjury, showing agreement in percentage 
of left ventricular infarction between MEMRI and DEMRI.33 
Interestingly, the investigators found no difference in signal 
intensity in regions of myocardium during infusion of manga-
nese, only observing the difference after termination of the 
infusion, suggesting that important uptake dynamics follow the 
initial perfusion phase. In permanent coronary artery occlusion 
myocardial infarction, the developers of EVP1001-1 reported a 
marked difference in longitudinal relaxation between infarcted 
and normal tissue, persisting for at least 1 hour.34 The investi-
gators did not quantify infarct size, simply reporting qualitative 
agreement between extent of infarction between EVP1001-1 
and histopathology, inferring clinical potential. Agreement 
between MEMRI infarct quantification using both MnDPDP 
and EVP1001-1 has been shown 12 weeks postinfarction by 
coronary artery ligation, with DEMRI overestimating infarct size 
acutely perhaps reflecting peri-infarct tissue oedema (figure 1).35
Myocardial viability and MeMRI
Beyond infarct quantification, MEMRI has the potential to assess 
myocardial viability. Using MnDPDP in acute ischaemia-reperfu-
sion injury by coronary artery ligation, MEMRI assessment of 
myocardium in vivo correlated with equivalent ex vivo MEMRI 
images17 as well as areas of regional wall motion abnormality.36 
Interestingly, areas of MEMRI enhancement were greater than 
histopathological quantification of infarcted myocardium,17 
suggesting that stunned myocardium also exhibits decreased 
manganese uptake.
The timing of manganese administration relative to injury 
has also been assessed. In a coronary artery ligation model 
of ischaemia reperfusion where MnDPDP was administered 
acutely with vessel occlusion, reduced MEMRI enhancement 
correlated with area at risk by methylene blue but interestingly 
not when administered >6 hours postreperfusion, when reduced 
MEMRI enhancement correlated with histopathological infarc-
tion.37 This implies that MEMRI enhances myocardium within 
injured but not infarcted myocardium and could be an important 
biomarker of viability. More recent studies have employed this 
principle using DEMRI and MEMRI together to identify peri-in-
farct viability, defined as regions which dual-enhance with both 
gadolinium and manganese.38 In the field of myocardial stem 
cell therapy, this approach has been reported to show successful 
engraftment in peri-infarct regions following ischaemia reper-
fusion by endovascular occlusion,39 highlighting the potential 
applications of MEMRI in the development of novel myocardial 
regenerative therapies.
Myocardial contractility and MeMRI
Dobutamine is a β1-adrenoceptor agonist, increasing myocardial 
calcium uptake through protein kinase A-mediated pathways 
and voltage-gated calcium channels by upregulating cyclic AMP 
figure 1 Preclinical manganese-enhanced MRI (MEMRI). MEMRI T1 mapping of acute myocardial infarction in a preclinical model of myocardial 
infarction in rat, with MnDPDP. Colour maps are configured to show infarct (pink) and remote myocardium (green) with an intermediate peri-infarct 
zone (yellow). Note the visibly smaller infarct size with MEMRI compared with DEMRI, more in line with histological description of infarct with 
Masson’s trichrome (MTC). DEMRI, delayed-enhancement MRI; MnDPDP, manganese dipyridoxyl diphosphate. 
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activity.40 MEMRI can detect pharmacological up-regulation 
and down-regulation of calcium-channel activity, using dobu-
tamine and diltiazem, respectively,41 demonstrating potential to 
assess the rate of myocardial calcium influx. In addition, dobuta-
mine stress clearly enhances the T1 shortening effect of manga-
nese on myocardium, independent of the rate of administration 
of contrast agent, suggesting increased manganese influx42 
with concomitant increase in efflux with dobutamine stress.32 
Furthermore, improved contrast between normal and isch-
aemic myocardium with greater reduction in remote myocardial 
T1 during both dipyridamole and dobutamine stress has been 
reported with EVP1001-1 in both acute and chronic models 
of ischaemia.29 The authors hypothesise that its rapid uptake 
kinetics mean EVP1001-1 alone, and not chelated MnDPDP, is 
suitable for stress imaging, although this has not been formally 
studied.
Altered calcium handling and MeMRI
Beyond detection and quantification of myocardial infarction 
and viability, there is a major clinical interest in whether MEMRI 
can describe more subtle alterations in calcium handling in 
various myocardial pathologies. In ischaemic remodelling, one 
study has looked at changes in T1 of the remote myocardium 
between early and late post-infarct time points.35 The authors 
observed a weak but significant correlation between impair-
ment of left ventricular ejection fraction and change in T1 over 
time, suggesting greater manganese uptake in remote remod-
elling myocardium of more severe ischaemic cardiomyopathy 
phenotypes. Animal models of non-ischaemic cardiomyopathy 
are limited but MEMRI in myocardial hypertrophy has been 
evaluated, with clear reduction in R1 of myocardium following 
pharmacological induction of hypertrophy compared with 
normal myocardium, mimicking hypertensive heart disease.43 
The cellular mechanisms underlying this have yet to be explored 
in detail, but it points to important potential of MEMRI for 
non-invasive detection of calcium dysregulation.
ClInICAl sTudIes wITH MeMRI
Despite extensive preclinical data, there are comparatively 
little clinical cardiac MEMRI data, with most using chelated 
agents. However, short-term cardiac safety of low-dose intrave-
nous manganese chloride (5 μmol/kg) in 15 healthy volunteers 
was explored, with T1 shortening properties commensurate 
with other data, without myocardial depression or toxicity.44 
Focussing only on short-term cardiac safety in healthy volun-
teers, further conclusions are limited. At the time of writing, 
there are no ongoing clinical trials investigating of manganese 
chloride in humans.
Building on extensive preclinical data, Skjold et al have 
demonstrated the effectiveness of MnDPDP in imaging human 
myocardium.45 They reported consistent reduction in T1 relax-
ation (34%–46%) in healthy myocardium 30 min after MnDPDP 
administration, observing only marginal differences in T1 relax-
ation rate between doses of 5, 10 and 15 μmol/kg. In a subse-
quent study, the investigators modelled the change in myocardial 
manganese concentration and unidirectional influx over time 
with different administration rates.46 Only minor differences 
in myocardial manganese uptake rate were observed between 
administration over 5 or 30 min, seen predominantly in the 
early infusion phase with similar overall concentrations in both 
groups. In patients with myocardial infarction, MEMRI could 
discriminate between infarcted and remote myocardium, with 
lower T1 in non-infarcted myocardium.47 Beyond acute myocar-
dial infarction, limited work has been done in chronic cardiomy-
opathy. To date, the data consist of a single conference abstract 
evaluating MEMRI in a small number of patients with severe 
chronic cardiomyopathy.48 Precontrast T1 quantified by turbo-
spin echo was higher than in healthy subjects, but still showed 
a sharp reduction after MnDPDP administration. Dramatically, 
lower T1 values were observed in a subset of patients with signal 
enhancement in dyskinetic regions, suggesting greater calci-
um-channel activity. These limited speculative findings require 
corroboration in validated clinical studies. One study is currently 
recruiting patients with ischaemic and non-ischaemic cardiomy-
opathy (NCT03607669), projecting a preliminary report later 
this year (figures 2 and 3, table 1).
In addition to extensive animal studies, EVP1001-1 has been 
evaluated in phase I and phase II clinical trials. The phase II 
clinical trial of this agent (NCT00340925) remains unpublished 
at the time of writing. A follow-up study (NCT01989195) has 
reported preliminary results in a small cohort of patients (n=6) 
with previous myocardial infarction which, although yet to be 
published, suggest minimal variation in heart rate and QRS 
duration with manganese, as well as significantly different quan-
tification of myocardial infarction for MEMRI compared with 
DEMRI (18.25±1.7 and 41%±11.4%, respectively). As with 
MnDPDP, clinical studies of EVP1001-1 have been undertaken 
to evaluate myocardial ischaemia and viability, yet to report 
(NCT02933034, NCT01989195, table 1).
sAfeTy ConCeRns oveR gAdolInIuM
Gadolinium-based contrast agents have been associated with 
nephrogenic systemic fibrosis. However, this has largely been 
eliminated by restricted use of these agents in renal disease, and 
avoidance of non-ionic linear agents. More recent concerns have 
arisen around neurological gadolinium deposition. Postmortem 
analysis has demonstrated neurological accumulation in patients 
without severe renal disease who had undergone intravenous 
gadolinium contrast administration, with undetectable levels in 
control subjects.1 This has led to the suspension of some linear 
gadolinium agents from the European market, with further work 
needed to clarify the propensity of macrocyclic agents to accu-
mulate in the central nervous system and to establish if this is 
associated with clinical sequelae. These safety concerns highlight 
our current dependence on gadolinium and the relative lack of 
alternatives.
figure 2 Clinical manganese-enhanced MRI (MEMRI). MEMRI 
T1 mapping in healthy myocardium with manganese dipyridoxyl 
diphosphate. Rapid reduction in T1 is seen in the blood pool, followed 
by rapid normalisation by 40 min. In contrast, the T1 value of remote 
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fuTuRe dIReCTIons
Myocardial imaging with MnDPDP relies on dissociation of 
manganese, whereby MEMRI is not easily applied to extracel-
lular or intravascular blood pool imaging. However, recent early 
clinical work shows the potential of a manganese-based contrast 
medium to provide contrast-enhanced magnetic resonance angi-
ography. Being highly resistant to dissociation, it provides similar 
angiographic results to gadolinium equivalents with the benefit 
of avoiding gadolinium administration.49
Recent studies have revisited the potential utility of manga-
nese radiotracers.50 While these have predominantly focused on 
applications in neuronal and pancreatic tissues, there is equal 
scope for application to cardiac imaging. This is especially 
relevant with the recent advances in hybrid positron emis-
sion tomography/MRI techniques, with potential for manga-
nese radiotracers to provide detailed structural and functional 
myocardial tissue characterisation.
As reviewed here, the ability of MEMRI to detect altered 
calcium handling is potentially ground breaking in the field. 
Unlike DEMRI, MEMRI offers exciting potential to diagnose 
and to quantify myocardial viability post-infarction, rather than 
infer likelihood of functional recovery based on anatomical 
scar assessment, offering more accurate prediction of disease 
progression. Beyond ischaemia, improved understanding of 
how non-ischaemic cardiomyopathic processes impact cellular 
calcium handling mechanisms may enable earlier diagnosis, 
improved prognostication and monitoring as well as guide novel 
therapeutic strategies.
Since the removal of Teslascan from the drug product list 
by the Food and Drug Administration (FDA) in 2003 and its 
withdrawal from the European market in 2012 by the market-
ing-authorisation holder, no manganese contrast medium has 
been clinically available. The reasons for this are multifactorial, 
involving lack of clinical demand due to safety and utility of 
gadolinium-based agents, as well as lack of large scale clinical 
translational MEMRI study despite promising clinical pilot data. 
It is important to highlight that no safety concern caused its with-
drawal, simply lack of clinical demand in hepatobiliary imaging. 
The formulation of MnDPDP for clinical use is clearly feasible, 
as evidenced by its current use in clinical studies (table 1). Simi-
larly, while EVP 1001-1 is not available for routine clinical use, 
it is currently undergoing clinical trial, again demonstrating the 
feasibility of manufacture of clinical manganese contrast agents. 
With promising clinical data emerging, a large scale translation 
is the essential next step to drive pharmaceutical interest in the 
production of these agents.
ConClusIons
With a significant body of preclinical data and emerging clinical 
work in the field, the stage is now set for wider clinical trans-
lation of this exciting non-invasive imaging technique. Poten-
tial applications are wide-reaching, including direct viability 
assessment following myocardial infarction, early diagnosis and 
pathophysiological study of non-ischaemic cardiomyopathy, and 
in development of novel regenerative heart failure therapies.
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